**Table S1.** Comparisons of baseline characteristics between patients who achieved clinical remission (DAS28-ESR < 2.6) at week 24 and those who did not.

|  |  |  |
| --- | --- | --- |
| 　 | ADD-ON (n = 98) | SWITCH (n = 96) |
| 　 | DAS28-ESR (24w) <2.6  | DAS28-ESR (24w) ≥2.6  | p value | DAS28-ESR (24w) <2.6  | DAS28-ESR (24w) ≥2.6  | p value |
| 　 | (n = 76) | (n = 22) | 　 | (n = 58) | (n = 38) | 　 |
| Age, year | 55 (±12) | 57 (±11) | 0.48 | 55 (±14) | 58 (±11) | 0.19 |
| Female, n | 69 (91%) | 19 (86%) | 0.69 | 51 (88%) | 35 (92%) | 0.74 |
| Height, cm | 157.5 (±6.6) | 157.7 (±6.4) | 0.88 | 158.2 (±7.8) | 155.0 (±6.9) | **0.0496** |
| Body weight, kg | 56.3 (±11.4) | 54.3 (±9.8) | 0.46 | 53.8 (±8.2) | 53.6 (±10.1) | 0.90 |
| BMI | 22.7 (±3.9) | 21.8 (±4.1) | 0.33 | 21.6 (±3.2) | 22.2 (±3.6) | 0.39 |
| Disease duration, year | 3.8 (±3.2) | 4.0 (±3.5) | 0.76 | 3.5 (±2.8) | 3.9 (±3.3) | 0.53 |
| PSL, mg/day | 0.0 [0.0,3.0] | 0.0 [0.0,4.8] | 0.61 | 0.0 [0.0,2.4] | 0.0 [0.0,4.0] | 0.56 |
| MTX\*, mg/week | 8.9 (±2.5) | 8.0 (±2.2) | 0.13 | 8.4 (±2.2) | 8.4 (±1.7) | 0.97 |
| CRP, mg/dL | 0.52 [0.13,1.81] | 0.57 [0.19,1.47] | 0.68 | 0.46 [0.08,1.50] | 1.51 [0.24,4.54] | **0.02** |
| IL-6, pg/mL | 15.5 [4.0,35.0] | 12.0 [4.1,41.3] | 0.78 | 12.7 [3.9,36.6] | 14.5 [6.7,35.5] | 0.71 |
| SAA, g/mL | 24.7 [6.6,106.5] | 25.6 [6.6,92.6] | 0.99 | 15.3 [8.9,37.4] | 85.0 [14.4,296.0] | **0.006** |
| MMP-3, ng/mL | 137.0 [69.5,233.0] | 90.1 [62.6,247.8] | 0.54 | 88.5 [60.4,241] | 109.0 [66.2,255.5] | 0.46 |
| RF, IU/mL | 56.9 [15.0,119.5] | 64.3[20.3,136.0] | 0.95 | 40.5 [26.0,120.7] | 81.2 [22.6,210.8] | 0.11 |
| IgG, mg/dL | 1439 (±421) | 1460 (±513) | 0.85 | 1506 (±380) | 1626 (±508) | 0.20 |
| TJC28 | 6.0 (±4.9) | 8.8 (±4.9) | **0.02** | 5.7 (±3.9) | 8.7 (±7.2) | **0.01** |
| SJC28 | 5.8 (±3.7) | 6.7 (±4.9) | 0.34 | 6.9 (±4.3) | 7.7 (±5.4) | 0.42 |
| ESR, mm/h | 37.6 (±27.2) | 49.0 (±26.8) | 0.09 | 39.3 (±27.9) | 55.1 (±32.4) | **0.01** |
| PGA, mm | 43 (±23) | 52 (±21) | 0.13 | 49 (±26) | 55 (±21) | 0.26 |
| TJC68 | 8.1 (±6.8) | 12.5 (±8.4) | **0.01** | 8.3 (±5.4) | 12.2 (±12.0) | **0.03** |
| SJC66 | 6.9 (±4.3) | 8.3 (±6.8) | 0.27 | 9.6 (±5.9) | 11.2 (±9.8) | 0.31 |
| EGA, mm | 46 (±21) | 44 (±21) | 0.74 | 48 (±20) | 49 (±20) | 0.89 |
| VAS Pain, mm | 47 (±23) | 54 (±20) | 0.18 | 50 (±25) | 53 (±23) | 0.66 |
| DAS28-ESR | 4.89 (±1.08) | 5.60 (±0.87) | **0.005** | 5.03 (±1.16) | 5.67 (±1.15) | **0.01** |
| CDAI | 20.7 (±9.8) | 25.1 (±9.8) | 0.07 | 22.5 (±10.0) | 26.8 (±13.3) | 0.07 |
| SDAI | 21.9 (±10.2) | 26.6 (±10.0) | 0.06 | 23.7 (±11.3) | 29.4 (±14.6) | **0.03** |

Variables are presented as mean (± standard deviation) or median [interquartile range]. \*: Represents the dose of MTX before tocilizumab initiation in SWITCH. BMI, body mass index; CDAI, clinical disease activity index; CRP, C-reactive protein; DAS28, disease activity score for 28 joints; EGA, evaluator global assessment; ESR, erythrocyte sedimentation rate; IgG. Immunoglobulin G; IL, interleukin; MMP, matrix metalloproteinase; MTX, methotrexate; PGA, patient global assessment; PSL, prednisolone; RF, rheumatoid factor; SAA, serum amyloid A; SDAI, simplified disease activity index; SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale.